Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
VBI Vaccines price target raised to $8 from $5 at Oppenheimer » 07:14
06/23/20
06/23
07:14
06/23/20
07:14
VBIV

VBI Vaccines

$2.61 /

-0.29 (-10.00%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell raised the firm's price target on VBI Vaccines to $8 from $5 and keeps an Outperform rating on the shares. The analyst notes that new VBI-1901's maturing Phase 1/2a results in refractory glioblastoma, as presented at AACR, include improvement from Stable Disease to a confirmed durable Partial Response in one patient with this highly aggressive malignancy; and VBI's identification of a biomarker that may predict immunotherapeutic response. Gershell looks forward to an initial reveal with a more active adjuvant in Q4, and a GBM registration trial is slated to begin next year. The analyst has revised his financial model to better reflect his view of VBI's prospects as it advances this and other pipeline assets as well as SciB-Vac, any/all of which he believes could drive industry partnerships.

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.61 /

-0.29 (-10.00%)

VBIV VBI Vaccines
$2.61 /

-0.29 (-10.00%)

03/31/20 BMO Capital
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital
11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
VBIV VBI Vaccines
$2.61 /

-0.29 (-10.00%)

VBIV VBI Vaccines
$2.61 /

-0.29 (-10.00%)

VBIV VBI Vaccines
$2.61 /

-0.29 (-10.00%)

Over a month ago
Hot Stocks
Culper Research short VBI Vaccines, says shares 'worthless' » 09:25
06/02/20
06/02
09:25
06/02/20
09:25
VBIV

VBI Vaccines

$2.00 /

-0.175 (-8.05%)

In a recently published…

In a recently published report, Culper Research says it is short VBI Vaccines as it believes the company "is effectively an 'empty box' stock promotion and shares are worthless." "We believe the Company's claim to a revolutionary hepatitis B vaccine (Sci-B-Vac) has fallen flat on its face. VBI's Sci-B-Vac acquisition traces to a paltry $2 million transaction in 2012, orchestrated by long-time stock promoter Phillip Frost. Investors now cheer on prospects for US and European approvals, but the Company's feeble clinical data package and consequent inability to secure a 2-dose label renders the drug practically worthless, in our view.... In what we believe is most damning both to Sci-B-Vac's commercial prospects and to management's credibility, on March 23, 2020, the European Medicines Agency (EMA) revealed it had refused Sci-B-Vac's pediatric investigation plan (PIP), stating that Sci-B-Vac 'does not represent a significant therapeutic benefit over existing treatments.'... In what we believe is most damning both to Sci-B-Vac's commercial prospects and to management's credibility, on March 23, 2020, the European Medicines Agency (EMA) revealed it had refused Sci-B-Vac's pediatric investigation plan (PIP), stating that Sci-B-Vac "does not represent a significant therapeutic benefit over existing treatments'," the report reads. Reference Link

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.00 /

-0.175 (-8.05%)

VBIV VBI Vaccines
$2.00 /

-0.175 (-8.05%)

03/31/20 BMO Capital
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital
11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
VBIV VBI Vaccines
$2.00 /

-0.175 (-8.05%)

VBIV VBI Vaccines
$2.00 /

-0.175 (-8.05%)

VBIV VBI Vaccines
$2.00 /

-0.175 (-8.05%)

Hot Stocks
VBI Vaccines forms commercial advisory board » 08:04
05/28/20
05/28
08:04
05/28/20
08:04
VBIV

VBI Vaccines

$2.16 /

-0.16 (-6.90%)

VBI Vaccines announced…

VBI Vaccines announced the formation of a commercial advisory board consisting of experts in public health policy, epidemiology and vaccine development. The board will work closely with VBI's management team on pre-commercialization and commercialization activities and strategy for the company's pipeline programs. Members of the commercial advisory board are Damian Braga, a member of the company's board who will act as chairperson, Eddy Bresnitz, Michael Decker and John Grabenstein.

ShowHide Related Items >><<
VBIV VBI Vaccines
$2.16 /

-0.16 (-6.90%)

VBIV VBI Vaccines
$2.16 /

-0.16 (-6.90%)

03/31/20 BMO Capital
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital
11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
VBIV VBI Vaccines
$2.16 /

-0.16 (-6.90%)

VBIV VBI Vaccines
$2.16 /

-0.16 (-6.90%)

VBIV VBI Vaccines
$2.16 /

-0.16 (-6.90%)

Periodicals
Big investment companies place cautious bets on COVID treatment race, WSJ says » 15:10
05/14/20
05/14
15:10
05/14/20
15:10
GILD

Gilead

$76.51 /

-0.53 (-0.69%)

, VBIV

VBI Vaccines

$2.15 /

+0.355 (+19.78%)

, VIR

Vir Biotechnology

$30.93 /

+0.19 (+0.62%)

As drug companies race to…

As drug companies race to discover treatments for the new coronavirus, big investment companies are placing cautious bets on likely winners, The Wall Street Journal's Gregory Zuckerman writes. Gilead (GILD) is up about 20% this year, thanks to remdesivir, but is among the stocks that has investors thinking twice, the author notes. Meanwhile, Robert Nelsen, who helps run venture-capital company Arch Venture Partners, which made early and successful bets on cancer immunotherapy, is backing VIR Biotechnology (VIR), which plans trials for its own monoclonal antibody therapy this summer, according to the report. Both Nelsen and Joseph Edelman, who runs Perceptive Advisors, also hold big chunks of ownership in VBI Vaccines (VBIV), an unproven biotech company claiming an experimental vaccine approach, Zuckerman adds.Reference Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$30.93 /

+0.19 (+0.62%)

VBIV VBI Vaccines
$2.15 /

+0.355 (+19.78%)

GILD Gilead
$76.51 /

-0.53 (-0.69%)

GILD Gilead
$76.51 /

-0.53 (-0.69%)

05/13/20 Piper Sandler
KOL sees remdesivir as COVID-19 standard of care, says Piper Sandler
05/13/20 JPMorgan
Gilead already given 'ample market credit' for remdesivir, says JPMorgan
05/11/20 RBC Capital
Gilead's U.S. remdesivir supply to be 'severely constrained', says RBC Capital
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
VBIV VBI Vaccines
$2.15 /

+0.355 (+19.78%)

03/31/20 BMO Capital
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital
11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
VIR Vir Biotechnology
$30.93 /

+0.19 (+0.62%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
VIR Vir Biotechnology
$30.93 /

+0.19 (+0.62%)

GILD Gilead
$76.51 /

-0.53 (-0.69%)

GILD Gilead
$76.51 /

-0.53 (-0.69%)

VIR Vir Biotechnology
$30.93 /

+0.19 (+0.62%)

VBIV VBI Vaccines
$2.15 /

+0.355 (+19.78%)

GILD Gilead
$76.51 /

-0.53 (-0.69%)

VIR Vir Biotechnology
$30.93 /

+0.19 (+0.62%)

VBIV VBI Vaccines
$2.15 /

+0.355 (+19.78%)

GILD Gilead
$76.51 /

-0.53 (-0.69%)

Syndicate
VBI Vaccines 45.455M share Spot Secondary priced at $1.10 » 09:14
04/22/20
04/22
09:14
04/22/20
09:14
VBIV

VBI Vaccines

$1.56 /

-0.03 (-1.89%)

Raymond James and…

Raymond James and Oppenheimer acted as joint book running managers for the offering.

ShowHide Related Items >><<
VBIV VBI Vaccines
$1.56 /

-0.03 (-1.89%)

03/31/20 BMO Capital
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital
11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
  • 22
    Apr
On The Fly
Fly Intel: After-Hours Movers » 18:58
04/21/20
04/21
18:58
04/21/20
18:58
SNAP

Snap

$12.44 /

-0.47 (-3.64%)

, USNA

Usana

$69.25 /

+2.32 (+3.47%)

, CMG

Chipotle

$781.00 /

-29.69 (-3.66%)

, TXN

Texas Instruments

$107.00 /

-4.31 (-3.87%)

, NFLX

Netflix

$434.01 /

-3.65 (-0.83%)

, EXPE

Expedia

$57.37 /

-2.55 (-4.26%)

, GME

GameStop

$4.78 /

-0.82 (-14.64%)

, QTNT

Quotient

$6.78 /

+0.27 (+4.15%)

, IBKR

Interactive Brokers

$43.27 /

-1.09 (-2.46%)

, MANH

Manhattan Associates

$52.00 /

-3.31 (-5.98%)

, NAVI

Navient

$6.56 /

-0.515 (-7.28%)

, VBIV

VBI Vaccines

$1.56 /

-0.03 (-1.89%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
SNAP Snap
$12.44 /

-0.47 (-3.64%)

04/21/20 Deutsche Bank
Snap price target lowered to $16 from $19 at Deutsche Bank
04/20/20 Credit Suisse
Snap price target lowered to $20 from $25 at Credit Suisse
04/20/20 Credit Suisse
Snap price target lowered to $20 from $25 at Credit Suisse
04/15/20 Pivotal Research
Snap price target lowered to $20 from $24.25 at Pivotal Research
USNA Usana
$69.25 /

+2.32 (+3.47%)

10/30/19 Stifel
Nu Skin upgraded to Hold on 'less bad' China expectations at Stifel
08/22/19 Jefferies
Jefferies starts Usana at Hold, says waiting on China rebound
08/22/19 Jefferies
Usana initiated with a Hold at Jefferies
07/03/19 Sidoti
Usana downgraded to Neutral from Buy at Sidoti
CMG Chipotle
$781.00 /

-29.69 (-3.66%)

04/17/20 Wolfe Research
Chipotle initiated with an Outperform at Wolfe Research
04/14/20 Cleveland Research
Chipotle comp sales appear to be better to start April, says Cleveland Research
04/13/20 Wedbush
Chipotle price target lowered to $860 from $980 at Wedbush
04/09/20 Wells Fargo
Chipotle price target lowered to $969 from $1,000 at Wells Fargo
TXN Texas Instruments
$107.00 /

-4.31 (-3.87%)

04/17/20 Barclays
Texas Instruments downgraded to Underweight from Equal Weight at Barclays
04/17/20 Barclays
Texas Instruments downgraded to Underweight from Equal Weight at Barclays
04/13/20 Morgan Stanley
Morgan Stanley downgrades Texas Instruments to Underweight on gross margins risk
04/13/20 Morgan Stanley
Texas Instruments downgraded to Underweight from Equal Weight at Morgan Stanley
NFLX Netflix
$434.01 /

-3.65 (-0.83%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 Loop Capital
Netflix price target raised to $490 from $415 at Loop Capital
04/17/20 BMO Capital
Netflix price target raised to $500 from $450 at BMO Capital
04/17/20 Rosenblatt
Netflix price target raised to $370 from $275 at Rosenblatt
EXPE Expedia
$57.37 /

-2.55 (-4.26%)

04/01/20
Fly Intel: Top five analyst downgrades
04/01/20 Argus
Expedia downgraded to Hold from Buy at Argus
04/01/20 Argus
Expedia downgraded to Hold from Buy at Argus
03/31/20 RBC Capital
Expedia price target lowered to $79 from $100 at RBC Capital
GME GameStop
$4.78 /

-0.82 (-14.64%)

03/27/20 Baird
GameStop trneds to remain weak despite recent increase, says Baird
03/20/20
Fly Intel: Top five analyst downgrades
03/20/20 Benchmark
GameStop does not qualify as an essential retailer, says Benchmark
03/20/20 Wedbush
GameStop downgraded to Neutral from Outperform at Wedbush
QTNT Quotient
$6.78 /

+0.27 (+4.15%)

IBKR Interactive Brokers
$43.27 /

-1.09 (-2.46%)

04/06/20 Wells Fargo
Broker sector has plenty of fundamental challenges, says Wells Fargo
03/06/20 Wells Fargo
Wells Fargo cuts price targets for brokers on lower interest rate environment
10/03/19 Wells Fargo
Wells Fargo downgrades E-Brokers after material commission cuts
10/02/19
Fly Intel: Top five analyst upgrades
MANH Manhattan Associates
$52.00 /

-3.31 (-5.98%)

04/14/20 SunTrust
Manhattan Associates price target lowered to $70 from $102 at SunTrust
02/18/20 Baird
Manhattan Associates initiated with an Outperform at Baird
08/15/19 Rosenblatt
Manhattan Associates initiated with a Buy at Rosenblatt
08/12/19 SunTrust
Manhattan Associates price target raised to $92 from $85 at SunTrust
NAVI Navient
$6.56 /

-0.515 (-7.28%)

04/09/20 Stephens
Stephens upgrades Navient to Overweight on government guarantee
04/09/20 Stephens
Navient upgraded to Overweight from Equal Weight at Stephens
03/17/20 Citi
Navient added to U.S. Focus List at Citi
03/17/20 Barclays
Navient upgraded to Overweight from Equal Weight at Barclays
VBIV VBI Vaccines
$1.56 /

-0.03 (-1.89%)

03/31/20 BMO Capital
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital
11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
  • 22
    Apr
Syndicate
VBI Vaccines announces common stock offering, no amount given » 16:06
04/21/20
04/21
16:06
04/21/20
16:06
VBIV

VBI Vaccines

$1.57 /

-0.025 (-1.57%)

VBI Vaccines announced…

VBI Vaccines announced that it has commenced an underwritten public offering of its common shares. VBI intends to use the net proceeds from the offering to support the regulatory filings, pre-commercialization, and launch planning activities for Sci-B-Vac in the United States, Europe, and Canada, for the continued advancement of its pipeline programs, including the development of VBI-1901, a cancer vaccine immunotherapeutic candidate for recurrent glioblastoma; VBI-2601, an immunotherapeutic candidate for chronic hepatitis B infection; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2901, a prophylactic pan-coronavirus vaccine candidate. The net proceeds will also be used for general corporate purposes, including working capital and capital expenditures. Raymond James and Oppenheimer are acting as joint book-running managers, and National Securities Corporation, a wholly-owned subsidiary of National Holdings, is acting as lead manager for the underwritten public offering.

ShowHide Related Items >><<
VBIV VBI Vaccines
$1.57 /

-0.025 (-1.57%)

03/31/20 BMO Capital
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital
11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
Over a quarter ago
Recommendations
VBI Vaccines COVID-19 program represents upside to estimates, says BMO Capital » 10:18
03/31/20
03/31
10:18
03/31/20
10:18
VBIV

VBI Vaccines

$1.04 /

+0.1155 (+12.49%)

VBI Vaccines this morning…

VBI Vaccines this morning announced a collaboration with the National Research Council of Canada to develop a novel pan-coronavirus vaccine for protection against COVID-19, in addition to severe acute respiratory syndrome and Middle East respiratory syndrome, BMO Capital analyst Do Kim tells investors in a research note. With VBI's eVLP platform technology, the multivalent vaccine could express all three viral spike proteins, as well as target mutated coronavirus strains, contends the analyst. Kim expects a potential lead candidate in Q4 of this year, with the program as upside to estimates. The analyst keeps an Outperform rating on VBI Vaccines with a $5 price target. The stock in early trading is up 15% to $1.08.

ShowHide Related Items >><<
VBIV VBI Vaccines
$1.04 /

+0.1155 (+12.49%)

11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
Hot Stocks
VBI teams with National Research Council of Canada for COVID vaccine » 10:13
03/31/20
03/31
10:13
03/31/20
10:13
VBIV

VBI Vaccines

$1.07 /

+0.1455 (+15.74%)

VBI Vaccines announced…

VBI Vaccines announced earlier today a collaboration with the National Research Council of Canada, Canada's largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The collaboration will combine VBI's viral vaccine expertise, eVLP technology platform, and coronavirus antigens with the NRC's COVID-19 antigens and assay development capabilities to identify the most immunogenic vaccine candidate for further development. Under the terms of the agreement, the NRC and VBI will collaborate to evaluate and select the optimal vaccine candidate. Following IND-enabling pre-clinical studies, VBI believes that clinical study materials could be available in Q4 2020. Said Francisco Diaz-Mitoma, VBI's Chief Medical Officer. "Coronaviruses are enveloped viruses by nature, which we believe makes them a prime target for VBI's flexible enveloped virus-like particle platform technology, ongoing development of which is led and conducted at our research facility in Ottawa, Canada. Based on past clinical experience with the eVLP platform, we expect that a multivalent eVLP vaccine candidate, co-expressing SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins on the same particle, will be possible to develop. Moreover, we believe the trivalent construct could allow for the production of broadly reactive antibodies, which offer potential for protection from mutated strains of COVID-19 that may emerge over time."

ShowHide Related Items >><<
VBIV VBI Vaccines
$1.07 /

+0.1455 (+15.74%)

11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
Hot Stocks
VBI Vaccines provides update on part A of VBI-1901 study » 08:11
03/03/20
03/03
08:11
03/03/20
08:11
VBIV

VBI Vaccines

$1.30 /

+ (+0.00%)

VBI Vaccines provided an…

VBI Vaccines provided an update on Part A of the ongoing Phase 1/2a study of VBI-1901, the company's cancer vaccine immunotherapeutic candidate, for the treatment of patients with recurrent glioblastoma, or GBM. For patients who had an immunologic response to the vaccine, considered to be vaccine responders, the 12-month overall survival, or OS, rate was 83%, compared to 33% for vaccine non-responders. Similarly, among patients evaluable for response and survival in Part A, vaccine responders saw a 6.25-month improvement in median OS compared to vaccine non-responders. VBI-1901 continues to be safe and well-tolerated at all doses tested, with no safety signals observed. Expanded immunologic, tumor imaging, and clinical data from the Phase 2a part of the study are expected in Q2 and Q4. Additionally, efforts are underway to define biomarkers that may help identify patients more likely to respond to VBI-1901.

ShowHide Related Items >><<
VBIV VBI Vaccines
$1.30 /

+ (+0.00%)

11/14/19 Raymond James
VBI Vaccines initiated with an Outperform at Raymond James
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.